

primary studies - published RCT

## **Growth hormone normalizes pubertal onset in children with cystic fibrosis.**

**Code:** PM16607924

**Year:** 2006 **Date:** 2009

**Author:** Vanderwel M

### **Study design (if review, criteria of inclusion for studies)**

RCT, parallel group, multicentre.

### **Participants**

78 people with CF; 42 children (8 - 17 yrs) and 36 adults (18 - 42 yrs).

### **Interventions**

1. TOBI® (300 mg/5 ml delivered by PARI LC PLUS); 2. Tobramycin PARI (150 mg/1.5 ml, delivered by an investigational eFlow), twice daily for 28 days.

### **Outcome measures**

Sputum concentration of tobramycin at 7 days of use. Serum levels of tobramycin at 7 days of use. Adverse events. Nebulisation time.

<http://dx.doi.org/10.1515/JPEM.2006.19.3.237>

### **See also**

J Pediatr Endocrinol Metab. 2006 Mar;19(3):237-44.

### **Keywords**

Anti-Bacterial Agents; Inhalation OR nebulised; pharmacological\_intervention; Tobramycin; Bacterial Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Infection; Aminoglycosides; nebuliser; non pharmacological intervention - devices OR physiotherapy;